Back to Search
Start Over
Mid-term outcome of de novo lesions vs. in stent restenosis treated by intravascular lithotripsy procedures: Insights from the French Shock Initiative.
- Source :
-
International Journal of Cardiology . Oct2022, Vol. 365, p106-111. 6p. - Publication Year :
- 2022
-
Abstract
- Intravascular lithotripsy (IVL) is a promising new technology for disrupting de-novo calcified coronary lesions (DNL) before percutaneous coronary intervention (PCI). We assessed 12-month outcomes of IVL in patients undergoing PCI for DNL or intra stent restenosis (ISR) lesions related to device underexpansion. Prospective analysis of patients in the multicentre all-comers French Shock Initiative IVL registry. The primary safety endpoints in this analysis were in-hospital and 12-month major adverse cardiovascular events (MACE: cardiac death, myocardial infarction or target vessel revascularization). The primary effectiveness endpoint was procedural success, defined as <30% residual stenosis without severe angiographic complications. Event rates were analysed for the cohort and for DNL and ISR procedures separately. A total of 220 lesions were treated (76.7% DNL and 23.3% ISR) in 202 patients. Procedural success was achieved in 95.5% of patients (DNL group: 96.5%; ISR group: 92.0%). In-hospital MACE occurred in 6.4% of cases, mainly driven by periprocedural infarctions. The rate of MACE-free survival at 1 year was 86.6% in the overall cohort. Rates of target vessel (TVR) and lesion (TLR) revascularisation were 6.4% and 2.5%, respectively. The 1-year MACE rate was 91.5% in DNL group and 83.8% in ISR group. In this large all-comers IVL cohort, rates of in-hospital and 1-year MACE were moderate. The safety and efficiency of IVL was comparable in DNL and ISR lesions. A comparative study of the impact of IVL on outcomes appears warranted. • A total of 220 lesions (76.7% de novo lesions / DNL and 23.3% intra stentrestenosis/ISR) were treated by intravascular lithotripsy in 202 patients. • Procedural success was achieved in 95.5% of patients, with no difference between DNL and ISR groups (96.5% vs 92%; p=0.24). • MACE-free survival at 1 year was 86.6% in the overall cohort, with no difference between DNL and ISR (91.5% vs 83.8%; p = 0.15). [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01675273
- Volume :
- 365
- Database :
- Academic Search Index
- Journal :
- International Journal of Cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 158672142
- Full Text :
- https://doi.org/10.1016/j.ijcard.2022.07.023